Generated by AI
Radiopharm Theranostics Limited Depositary Receipt is the U.S.-traded depositary receipt for Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company focused on radiopharmaceutical products for diagnostic imaging and targeted therapy. The company develops oncology-focused technologies designed to address areas of high unmet medical need, with programs spanning both pre-clinical and clinical stages of development. Its current pipeline includes diagnostic and therapeutic candidates built around radiopharmaceutical platforms for cancer targeting, reflecting a business centered on precision medicine and molecular imaging. Radiopharm Theranostics Limited serves researchers, clinicians, and healthcare stakeholders working in cancer diagnosis and treatment, and its depositary receipt provides a market-facing representation of the company’s ordinary shares for international investors.
Website62 Lygon Street
Carlton, VIC, 3053
Australia
The latest articles about RADX.
Tipranks Press Release.
Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds Radiopharm Theranostics advancing preparations for Phase 3 study with clinical supply of 18F-labeled RAD101 from partnership with Siemens Healthineers Company expects to complete CRO selection in the fourth quarter 2026, initiate site activations and begin dosing patients in first half 2027 SYDNEY, Nov. 04, 202
Summary of Nov 17's posts. Generated by AI.
Summary of Jul 24's posts. Generated by AI.
Summary of Jul 24's posts. Generated by AI.
Investors talking about RADX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.